Aimovig OverviewErenumab (trade name Aimovig) is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It was the first of the group of CGRPR antagonists to be approved in 2018. Contents 1 Uses 2 Pharmacology 3 History 3.1 Development 3.2 Approval and marketing 4 See also 5 References Uses Erenumab is approved for prevention of migraine in adults. It is administered by subcutaneous injection of 70 or 140mg once a month.[6...
Read more Aimovig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Erenumab
Recent Aimovig Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 70mg/ml
NDC Database Records for Aimovig: (2 results)Sorted by National Drug Code
- 55513-840 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc
- 55513-841 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc